1,3-DMAA

1,3-Dimethylamylamine (1,3-DMAA), also called methylhexanamine, methylhexaneamine, or by the trade name Geranamine, is a synthetic aliphatic amine with central nervous system stimulant activity. Chemically it is a simple branched alkylamine (4-methylhexan-2-amine) that lacks the aromatic ring of the amphetamines yet produces broadly sympathomimetic effects. It was first patented in the 1940s as a nasal decongestant and later resurfaced as a recreational and performance stimulant ^[3].

From the mid-2000s onward, DMAA became a headline ingredient in pre-workout and weight-loss supplements, where it was frequently marketed as a natural constituent of geranium (Pelargonium graveolens) oil under names such as Geranamine ^[2]. That claim triggered a prolonged scientific dispute. Independent analyses using gas chromatography, HPLC-MS, and related methods repeatedly failed to detect DMAA in authentic geranium plant material or oils sourced from multiple regions, concluding that supplement DMAA is synthetic rather than botanical ^[1][2]. The conflicting reports in the literature have been attributed largely to differences in source material and extraction methodology ^[1].

Commercially, DMAA appeared as the hydrochloride salt in capsules, powders, and pre-workout blends, very often paired with caffeine ^[6][7]. Analytical surveys documented highly variable content between products and confirmed its identity by NMR and mass spectrometry ^[8]. Regulators subsequently acted against it; authorities classified DMAA as an unapproved and unlawful ingredient rather than a legitimate food component, and it is banned in competitive sport as a doping agent ^[3][8]. Pharmacokinetic work in humans has since characterized its absorption and elimination, reporting a terminal half-life of roughly 8 hours after a single oral dose ^[5]. Today it is studied chiefly in analytical chemistry, toxicology, and anti-doping contexts.

1,3-DMAA (methylhexanamine) is a potent sympathomimetic stimulant that constricts blood vessels and raises heart rate and blood pressure. It has been linked to serious cardiovascular events including hypertensive crisis, arrhythmia, stroke, cerebral hemorrhage and deaths, especially during exertion or when combined with caffeine or other stimulants, and regulators including the US FDA have warned against its use in supplements. It may also trigger chest tightness, anxiety, and headaches and can produce positive athletic drug tests.

1,3-DMAA (methylhexanamine) is an indirect sympathomimetic amine, and controlled dosing studies show it raises blood pressure, an effect that is additive when combined with caffeine, the pairing most common in the supplements that caused reported harms. Case reports link DMAA, frequently taken with caffeine or other stimulants, to hypertensive crises, hemorrhagic and ischemic stroke, myocardial infarction, and sudden death. Because it promotes catecholamine activity, combining it with monoamine oxidase inhibitors carries a pharmacologically expected risk of hypertensive crisis, and stacking it with other stimulants or sympathomimetic decongestants compounds cardiovascular strain. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

1,3-DMAA, chemically 1,3-dimethylamylamine or methylhexanamine, was introduced by the pharmaceutical company Eli Lilly in the 1940s and marketed under the trade name Forthane as an inhaled nasal decongestant, an application that reflected its vasoconstrictive action on nasal mucosa. It faded from pharmaceutical use for decades before being reintroduced in the mid-2000s as an ingredient in dietary supplements and pre-workout formulas, where it became one of the defining stimulants of the hardcore pre-workout era. Its rise prompted scrutiny from regulators and anti-doping authorities, who moved to restrict it amid case reports linking heavy or combined use to serious cardiovascular events. Controlled studies have characterized its pharmacokinetics and its pronounced pressor effect, cementing its profile as a potent but risk-laden sympathomimetic.

1,3-DMAA earned an almost legendary reputation in sports nutrition as one of the most intense stimulants ever sold, prized for the clean energy, sharp focus, and appetite suppression it delivered in pre-workout formulas. That reputation is real, and controlled trials confirm its distinctive vasoconstrictive, adrenergic character. The candid counterweight is that the same pressor profile is its central liability: studies document meaningful acute increases in blood pressure, and case reports have associated heavy or stacked use with events such as cerebral hemorrhage, which is why regulators moved against it. It is fairly remembered as a powerful but genuinely risk-bearing compound whose intensity was inseparable from its cardiovascular effects.